Five years after settling, GSK is again accused of breaching the Jemperli deal.
ApexOnco Front Page
Recent articles
Arcellx and AstraZeneca take centre stage.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
The response rate jumps to 30% with higher doses of IMA402.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
After more discontinuations, a new deal brings in fresh blood.
The CD70-targeting CTX131 heads for the scrapheap.
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
